1
|
Gettens Bourgea KM, Erkkinen M, Gale SA, McGinnis SM, Daffner KR, Silbersweig D, Schildkrout B. Case Studies 7A and 7B: Two Physician-Patients With Early Alzheimer's Disease and Differing Levels of Insight. J Neuropsychiatry Clin Neurosci 2024; 36:220-227. [PMID: 38835225 DOI: 10.1176/appi.neuropsych.20230217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2024]
Affiliation(s)
- Katelyn M Gettens Bourgea
- Departments of Neurology (Gettens Bourgea, Erkkinen, Gale, McGinnis, Daffner) and Psychiatry (Silbersweig, Schildkrout), Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Michael Erkkinen
- Departments of Neurology (Gettens Bourgea, Erkkinen, Gale, McGinnis, Daffner) and Psychiatry (Silbersweig, Schildkrout), Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Seth A Gale
- Departments of Neurology (Gettens Bourgea, Erkkinen, Gale, McGinnis, Daffner) and Psychiatry (Silbersweig, Schildkrout), Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Scott M McGinnis
- Departments of Neurology (Gettens Bourgea, Erkkinen, Gale, McGinnis, Daffner) and Psychiatry (Silbersweig, Schildkrout), Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Kirk R Daffner
- Departments of Neurology (Gettens Bourgea, Erkkinen, Gale, McGinnis, Daffner) and Psychiatry (Silbersweig, Schildkrout), Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - David Silbersweig
- Departments of Neurology (Gettens Bourgea, Erkkinen, Gale, McGinnis, Daffner) and Psychiatry (Silbersweig, Schildkrout), Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
| | - Barbara Schildkrout
- Departments of Neurology (Gettens Bourgea, Erkkinen, Gale, McGinnis, Daffner) and Psychiatry (Silbersweig, Schildkrout), Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
| |
Collapse
|
2
|
The Relationship Between Decision-making Capacity and the Domains of Awareness in Alzheimer Disease. Alzheimer Dis Assoc Disord 2022; 36:58-63. [PMID: 35090160 DOI: 10.1097/wad.0000000000000484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 11/10/2021] [Indexed: 11/26/2022]
Abstract
People with Alzheimer dementia (PwAD) who are aware of their overall cognitive function and diagnosis are more likely to be judged competent in decision-making capacity. Therefore, we aimed to investigate the relationship between decision-making capacity and the different domains of awareness and the relationship between decision-making capacity and the cognitive and clinical impairment of the PwAD. Using a cross-sectional design, we included 121 PwAD and their caregivers. Awareness was assessed across domains, including cognitive functioning and health condition, functional activity impairments, emotional state, social functioning, and interpersonal relationships. The MacArthur Competence Assessment Tool for Treatment was adopted to gather information about decision-making abilities. We found that decision-making capacity is related to the cognitive and functional domains of awareness and relatively independent of the emotional functioning and the relationship domains. Our finding highlighted that PwAD who are unaware of the disease or the cognitive and functional impairments might be unlikely to appreciate the personal benefits of a proposed health treatment or to understand and judge the personal consequences of a decision accurately.
Collapse
|
3
|
Flores-Vázquez JF, Ramírez-García G, Marrufo-Meléndez OR, Alcalá-Lozano R, Lietz MP, Rodríguez-Agudelo Y, Acosta-Castillo GI, Renken RJ, Aleman A, Enriquez-Geppert S, Sosa-Ortiz AL. Anosognosia in Amnestic Mild Cognitive Impairment Is Related to Diminished Hippocampal Volume Comparable to Alzheimer's Disease Dementia: Preliminary MRI Findings. Front Aging Neurosci 2021; 13:739422. [PMID: 34776927 PMCID: PMC8581404 DOI: 10.3389/fnagi.2021.739422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Accepted: 10/05/2021] [Indexed: 12/03/2022] Open
Abstract
Although the presence of anosognosia in amnestic mild cognitive impairment (aMCI) may be predictive of conversion to Alzheimer’s disease (AD), little is known about its neural correlates in AD and aMCI. Four different groups were compared using volumetric and diffusion magnetic resonance imaging metrics in regions of interest (hippocampus and cingulum cortex gray matter, cingulum bundle white matter): aMCI subjects with anosognosia (n = 6), aMCI subjects without anosognosia (n = 12), AD subjects with anosognosia (n = 6), and AD subjects without anosognosia (n = 9). aMCI subjects with anosognosia displayed a significantly lower gray matter density (GMD) in the bilateral hippocampus than aMCI subjects without anosognosia, which was accounted for by bilateral hippocampal differences. Furthermore, we identified that the mean hippocampal gray matter density of aMCI subjects with anosognosia was not statistically different than that of AD subjects. The groups of aMCI and AD subjects with anosognosia also displayed a lower GMD in the bilateral cingulum cortex compared to subjects without anosognosia, but these differences were not statistically significant. No statistically significant differences were found in the fractional anisotropy or mean diffusivity of the hippocampus or cingulum between subjects with and without anosognosia in aMCI or AD groups. While these findings are derived from a small population of subjects and are in need of replication, they suggest that anosognosia in aMCI might be a useful clinical marker to suspect brain changes associated with AD neuropathology.
Collapse
Affiliation(s)
- Juan Francisco Flores-Vázquez
- Programa de Maestría y Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Universidad Nacional Autónoma de México, Mexico City, Mexico.,Laboratorio de Demencias, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.,Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, Netherlands.,Section of Cognitive Neuropsychiatry, Department of Biomedical Sciences of Cells and Systems, University of Groningen, Groningen, Netherlands
| | - Gabriel Ramírez-García
- Laboratorio de Neuropsicología, Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - Oscar René Marrufo-Meléndez
- Unidad de Neuroimagen, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico
| | - Ruth Alcalá-Lozano
- Subdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Morten Peter Lietz
- Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, Netherlands.,Section of Cognitive Neuropsychiatry, Department of Biomedical Sciences of Cells and Systems, University of Groningen, Groningen, Netherlands
| | - Yaneth Rodríguez-Agudelo
- Departamento de Neuropsicología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico
| | - Gilberto Isaac Acosta-Castillo
- Programa de Maestría y Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Universidad Nacional Autónoma de México, Mexico City, Mexico.,Laboratorio de Demencias, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico
| | - Remco J Renken
- Section of Cognitive Neuropsychiatry, Department of Biomedical Sciences of Cells and Systems, University of Groningen, Groningen, Netherlands
| | - Andre Aleman
- Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, Netherlands.,Section of Cognitive Neuropsychiatry, Department of Biomedical Sciences of Cells and Systems, University of Groningen, Groningen, Netherlands
| | - Stefanie Enriquez-Geppert
- Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, Netherlands.,Section of Cognitive Neuropsychiatry, Department of Biomedical Sciences of Cells and Systems, University of Groningen, Groningen, Netherlands
| | - Ana Luisa Sosa-Ortiz
- Programa de Maestría y Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Universidad Nacional Autónoma de México, Mexico City, Mexico.,Laboratorio de Demencias, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico
| |
Collapse
|